Sensitive and Validated Voltammetric Methods for Determination of Zileuton in Serum, Urine and Pharmaceutical Dosage Forms at Activated Glassy Carbon Electrode

NABIL A. ALHEMIARY^{1,2,*} and MOUSTFA A. RIZK^{1,3}

¹Department of Chemistry, College of Science and Arts - Sharurah, Najran University, Sharurah, Saudi Arabia

²Department of Chemistry, College Science, Ibb University, Ibb, Yemen

³Department of Chemistry, College of Science, Suez Canal University, Ismailia, Egypt

*Corresponding author: E-mail: alhemyri1000@yahoo.com

Received: 27 April 2017;

Accepted: 11 September 2017;

Published online: 30 October 2017;

AJC-18604

A simple, precise and sensitive voltammetric methods determination of zileuton were presented at activated glassy carbon electrode in Britton-Robinson buffer of pH 8 by differential pulse voltammetry and square wave voltammetry methods. A study of the variation of the peak current with solution variables such as pH, ionic strength, concentration of drug, possible interference and instrumental variables such as scan rate, pulse amplitude, accumulation potential, has resulted in the optimization of the reduction signal for analytical purposes. Linear calibration plots were obtained over the concentration ranges of 2.0×10^{-6} to 1.2×10^{-5} and 1.0×10^{-6} to 1.8×10^{-5} mol/L, respectively, using differential pulse voltammetry and square wave voltammetry methods. The correlation coefficients were 0.9977 and 0.9947 for differential pulse voltammetry and square wave voltammetry methods, respectively. The linear response was obtained in Britton-Robinson buffer in the range of 2.0×10^{-6} – 2.0×10^{-5} and 2.0×10^{-6} – 3.1×10^{-5} mol/L for spiked serum and urine samples, respectively. The limit of detection (LOD) and limit of quantification (LOQ) were 1.3×10^{-9} and 3.95×10^{-9} mol/L for differential pulse voltammetry method and 2.34×10^{-10} and 6.99×10^{-10} mol/L for square wave voltammetry method. The RSD for five measurements were 0.0489 and 0.0885 using 50 mV/s scan rate. The methods were applied for the determination of zileuton drug in dilute serum, urine samples and pharmaceutical dosage form with satisfactory results and compared with the official reference method. Complete validation of the proposed method was also done.

Keywords: Zileuton, Differential pulse voltammetry, Square wave voltammetry, Cyclic voltammetry, Activated glassy carbon electrode.

INTRODUCTION

Zileuton [R,S-(±)-N-(1-(benzo[b]thien-2-yl) ethyl)-N-hydroxyurea] (Fig. 1) and is an anti-asthma drug that differs chemically and pharmacologically from other anti-asthmatic agents [1,2]. Zileuton is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older [3]. It blocks leukotriene synthesis by inhibiting 5-lipoxygenase, an enzyme of the eicosanoid synthesis pathway [1]. Current data indicates that asthma is a chronic inflammatory disorder of the airways involving the production and activity of several endogenous inflammatory mediators, including leukotrienes. Sulfido-peptide leukotrienes (LTC₄, LTD₄, LTE₄, also known as the slow-releasing substances of anaphylaxis) and LTB₄ [4,5]. A chemoattractant for neutrophils and eosinophils are derived from the initial unstable product of arachidonic acid metabolism, leukotriene A₄ (LTA₄) and can be measured in a number of biological fluids including broncho alveolar lavage fluid (BALF) from asthmatic patients [6]. In humans, pretreatment with zileuton attenuated broncho-

Fig. 1. Structure of zileuton

constriction caused by cold air challenge in patients with asthma [7]. Zileuton is a very slightly soluble compound without any ionizable functional group [8]. Recently, the molecule has been reported in the literature as a new efficient and safe antiacne drug [9]. The methods available for analysis of zileuton in pharmaceutical dosage forms and biological fluids are those utilizing the principles of UV and VIS-spectrophotometry [10,11], HPLC [12-14], HPTLC [15], RP-HPLC [16,17], LC/MSMS [18,19] and polarography [20].

The advantages of electrochemical techniques in drug analysis are their simplicity, low cost and relatively short analysis time compared with other routine analytical techniques. In

the present study, electrochemical behaviour and oxidation-reduction mechanism of zileuton at an activated glassy carbon electrode was investigated using cyclic voltammetry (CV), differential pulse voltammetry (DPV) and square wave voltammetry (SWV). Determination of zileuton in spiked urine, spiked serum samples and in pharmaceutical dosage forms was also investigated using DPV and SWV.

EXPERIMENTAL

The electrochemical analyzer computerized system with 797 VA computerized software (1.0) from Metrohm, Switzerland was used. A three-electrode system was used, including a glassy carbon electrode as the working electrode. A digital pH/mV meter (Jeanway 3510) with a glass combination electrode was used for the preparation of the buffer solution. An Oxford adjustable micropipette (Huawei, Ireland) was used to measure microliter volumes of the drug standard solutions. The sigma 4-5 L centrifuge, Sigma (USA) was used to centrifuge the urine and serum samples, which were then suitable for voltammetric analysis.

The chemicals and reagents used were of analytical reagent grade and some of them were used as such without any further purification. Distilled water was used throughout all experiments. Zileuton (purity 99.8 %) were supplied by Spimaco Addwaeih, Al-Qassim, Saudi Arabia. Stock solution of 1.0×10^{-3} mol/L zileuton was freshly prepared by dissolving a calculated weighed of the active ingredient drugs in deionized water and stored at 4 °C in PVC containers. More diluted solutions were freshly prepared daily by accurate dilution. 0.04 mol/L Britton-Robinson buffer between pH 4-12 were used as the supporting electrolytes. All solutions were prepared from AnalaR grade reagents (Sigma-Aldrich) in doubly distilled water. The calibration curves for DPV and SWV analysis were constructed by plotting the peak current against zileuton concentration.

Optimizations: To obtain the optimum pH, an appropriate amount of zileuton working standard solution 1×10^{-3} mol/L was placed in the electrolytic cell, which contained 25 mL of Britton-Robinson buffer solution and the cyclic voltammogram was recorded. The experiment was repeated by using buffer solutions of different pH values 4-12 and the optimum pH was obtained. The effect of different types buffer such as acetate, phosphate and Britton-Robinson buffer on the peak current (I_p) of zileuton was studied. The working electrode was immersed in buffer solution of the optimum pH containing an appropriate amount of the drug stock solution 1×10^{-3} mol/L, the cyclic voltammogram was recorded. For analytical application, the following parameters being employed: DPV-pulse amplitude 50 mV, pulse width 50 ms, scan rate 50 mV/s, SWV-pulse amplitude 25 mV, frequency 15Hz, potential step 4 mV, electrochemical analyzer does the background subtraction automatically. For cyclic voltammetry, the initial and final potential values were variable, depending on the pH value and the cut-off the electrolyte. Scan rate measurements in the range of 10-200 mV/s were carried out.

Pre-treatment of glassy carbon electrode: The electrode was pretreated by cycling a square-wave potential with a frequency of 350 Hz between the potential limits of ± 6 V followed by the application of triangular potential sweep between ± 6 V (frequency 3500 Hz) in 0.1 mol/L potassium nitrate solution.

Finally, the electrode was subjected to an electrochemical pretreatment by applying a potential of +1.5 V for 5 min and then -1.0 V for 2 s in 0.1 mol/L potassium nitrate solution. These steps were repeated until the voltammetric response of the electrode became reproducible. At the end of the procedure, the electrode surface was so stable that for 40 measurements, the electrochemical pretreatment alone was sufficient before each scan [21].

General procedure: Voltammetric analyses were performed in 25 mL of Britton-Robinson buffer. The solution was continuously stirred at 1200 rpm when accumulation potential (usually open circuit conditions) was applied for a certain time to the working electrode. At the end of accumulation period, the stirring was stopped and after 5.0 s rest period was allowed for the solution to become quiescent. The used drug was determined by using DPV method. Aliquots of the drug solution of 1×10^{-3} mol/L were introduced into the electrolytic cell and the procedure was repeated. The voltammograms were recorded. The peak current was evaluated as the difference between each voltammogram and the background electrolyte voltammogram. All measurements were carried out at room temperature.

Analysis of pharmaceutical dosage form: Tablets containing 600 mg of zileuton per tablet were purchased from local Saudi Arabia market. Ten tablets of zileuton were crushed into a fine powdered in a mortar. A suitable amount of this powder was accurately weighed and then dissolved in 25 mL methanol. It was sonicated for 5 min. The content was allowed to settle after stirring magnetically for 5 min. The sample solution was filtered through a Whatman no. 42 filter paper. Appropriate solutions were prepared by taking suitable aliquots of the clear supernatant liquid and diluting them with bidistilled water in order to obtain a final solution of 1.0×10^{-3} mol/L zileuton. Each solution was transferred to a voltammetric cell and the voltammograms were subsequently recorded following the optimized conditions. The amount of zileuton per tablet was calculated using linear regression equation obtained from the calibration curve of pure zileuton.

Analysis of spiked biological samples: The urine and serum samples, obtained from healthy volunteers was centrifuged (4000 rpm) for 30 min at room temperature and separated. Serum samples were stored frozen until assay. After gentle thawing, an aliquot volume of samples were fortified with drug sample dissolved in deionized water to achieve final concentration of 1×10^{-3} mol/L and treated with 0.4 mL acetonitrile as serum denaturing and precipitating agent. Acetonitrile is known to remove serum proteins more effectively. The volume was completed to 3 mL with the same serum sample. The tube was vortexed for 1 min and then centrifuged for 10 min at 4000 rpm to get rid of serum protein residues and supernatant was taken carefully. Appropriate volumes of the clean solution were analyzed in the voltammetric cell containing Britton-Robinson buffer, pH 8.0. Quantification were performed by means of calibration curve methods [22,23].

RESULTS AND DISCUSSION

Cyclic voltammetry: Anodic cyclic voltammogram for the oxidation-reduction of zileuton in Britton-Robinson buffer at activated glassy carbon electrode is shown in (Fig. 2). It is

clear that the voltammogram exhibits one anodic and cathodic peaks at 943 mV and 420 mV, respectively, which shows a quasi-reversible behaviour, with peak-to-peak separation ($\Delta E_p = |E_{pc} - E_{pa}|$) of -523 mV. The results suggest the redox couple which shows reversible behaviour with equal number of protons and electrons participated in the working buffer. The zileuton may undergoes protonation with bond cleavage and one electron loss in the first oxidation step. Then the oxidized product was reduced *via* gaining electron and deprotonation of the oxidized product. The proposed mechanism of oxidation-reduction reaction is shown in **Scheme-I**.

Fig. 2. Cyclic voltammogram of 1×10^{-6} mol/L zileuton in Britton-Robinson buffer at pH 8.0; scan rate = 50 mV/s

Effect of pH: The pH of the electrolyte medium is one of the variables that commonly and strongly influenced the shape of the voltammogram and therefore it was important to investigate the effect of the pH on the electrochemical behaviour of the drug. The effect of pH on the reduction of the drugs under investigation at activated glassy carbon electrode was studied over the pH range 4-12 at same concentration 1.0×10^{-3} mol/L of zileuton solution in various electrolytes, such as acetate, phosphate and Briton-Robinson buffers of different ionic strength in the range of 0.04-0.2 mol/L. It was found that the maximum peak size was obtained at pH 8 in Britton-Robinson buffer, which allows wider range of determination than acetate and phosphate buffers. Hence, it was used as a favourable buffer throughout the study. Fig. 3 shows the effect of pH on the current peak in a Briton-Robinson buffer of pH range from 4 to 10 for 2.0×10^{-6} mol/L zileuton.

The effect of solution pH on peak potentials of zileuton at GCE was also investigated. Cyclic voltammograms at different pH values of 4-12 were shown in Fig. 3., which show that an increase in pH of the solution caused shift in the oxidative peak potential to the negative direction, indicating that the electrode process is influenced by protonation reactions. A linear correlation between the peak potential and solution pH was obtained as shown in Fig. 4 with a linear equation and correlation of:

Fig. 3. Cyclic voltammogram obtained for 2.0×10^{-6} mol/L zileuton in Britton-Robinson buffer solution at (a) pH 4.0, (b) pH 6.0, (c) pH 8, (d) pH 10 and (e) pH 12 with potential; scan rate: 50 mV/s

$$E_{pa} \text{ (mV/s)} = 1.811 - 0.114 \text{ pH} \quad r = 0.9911$$

The slope was found to be 0.114 mV/pH, which suggested that the number of proton taking part in the electrode reaction is similar to the number of electrons. Hence, the oxidation of zileuton involves one electron and one proton.

Fig. 4. A linear correlation between the peak potential and pH

Effect of scan rates: The relationship between measured peak current and scan rate was studied over range 10-200 mV/s. It was found to be directly proportional the peak current and the peak potential of zileuton were evaluated as shown in Fig. 5. Scan rate studies were carried out to assess whether the process at the glassy carbon electrode was under diffusion or adsorption controlled process as shown in Fig. 6. The anodic and cathodic peak current of zileuton increases linearly with the square root of scan rate, in the potential range from 10 to 200 mV, with egression $r = 0.9954$. A plot of logarithm of peak current *versus* logarithm of scan rate gave a straight line with a slope very close to the theoretical value of 0.5, which is expressed for an ideal reaction of diffusion controlled electrode process (Fig. 7) [24]. Also the anodic and cathodic peak potentials of the electrode were shifted toward positive and negative potential,

Scheme-I: Proposed mechanism of the oxidation-reduction reaction of zileuton drug

Fig. 5. Cyclic voltammograms of 2.0×10^{-6} mol/L zileuton in Britton-Robinson buffer at pH 8 at scan rates of: (1) 10, (2) 30, (3) 50, (4) 80, (5) 100, (6) 200 mV/s

Fig. 6. The anodic (a) and cathodic (b) peak current of zileuton with the square root of scan rate

respectively. This may be attributed to the accumulation of the oxidation or reduction products on the electrode surface.

Effect of accumulation operators: The accumulation of zileuton at GCE surface depends on operational factors, which were additional investigations to ensure sensitive detections of this drug [25]. So, the effect of accumulation time on the efficiency of the collection of 1×10^{-3} mol/L zileuton drug on the working electrode surface was evaluated by rising the accumulation time over the range of 0–40 s. The resulting peak current-optimum accumulation time is exhibited in 30 s (Fig. 8) and as can be seen from this plot, a steady enhancement in the peak current was observed over the range 0–40 s and after that the peak intensity nearly decreased probably due to the satu-

Fig. 7. Relation between $\log i_p$ (μA) and $\log$ scan rate (V/s) for oxidation of zileuton drug at activated glassy carbon electrode

Fig. 8. Effect of accumulation time (t_{acc}) of 2×10^{-6} mol/L zileuton peak current at Britton-Robinson buffer, pH = 8, $E = 0.1$ V and scan rate 50 mV/s

ration of the GCE surface. Hence, 30 s accumulation time was selected for all the future experiments. In a different study, the accumulation potential effect on the peak current of this drug was recorded by variation of accumulation potential from 0.15 V to -0.6 V. The maximum anodic peak current value was obtained with an accumulation potential of 0.1 V, which was selected as the optimum value in future experimental studies.

Analytical applications: While the sensitivity enhancement associated with the interfacial accumulation is significant, the main advantage of the method is its inherent selectivity towards the surface-bound analyte. For this purpose the working electrode with the extracted drug was transferred from the complex

sample to an electrolytic blank solution between the preconcentration and measurement steps.

Differential pulse voltammetry: To develop a quantitative voltammetric evaluation methodology for determining the drug was established on the linear correlation between the peak current and concentration. For analytical purposes we selected the DPV and SWV mode. Differential pulse experiments were performed on the GCE in Britton-Robinson buffer solution at pH = 8 with experimental conditions were: scan rate 50 mV s^{-1} ; pulse amplitude 50 mV ; pulse width of 50 ms and pulse period 40 ms . The potential was scanned anodically from an initial to a final potential of $400\text{--}1200 \text{ mV}$ resulting voltammograms shown in Fig. 9, which show that while the peak potential remained almost constant at 0.892 V , the DPV data for the determination of the drug under investigation (Fig. 10) shows a linear relation between the peak current (I_p) and zileuton concentration (C) and was found in the following range: $2 \times 10^{-6} - 1.2 \times 10^{-5} \text{ mol/L}$.

Fig. 9. Differential-pulse voltammograms with increasing concentration of zileuton ($2 \times 10^{-6} - 1.2 \times 10^{-5} \text{ mol/L}$) in pH 8 buffer solution on GCE electrode

Fig. 10. Calibration graphs of zileuton drug by using DPV method

Square wave voltammetry: The SWV experiments were performed at GCE in Britton-Robinson buffer solution at pH = 8 with experimental conditions were: scan rate 50 mV s^{-1} ; pulse amplitude 25 mV ; 4 mV potential step and potential range of 500 to 1000 mV and frequencies 50 Hz . The potential was scanned anodically from an initial to a final potential of $400\text{--}1200 \text{ mV}$ resulting voltammograms are shown in Fig. 11. It

shows that while the peak potential remained almost constant at 0.866 V , the SWV data for the determination of the drug under investigation (Fig. 12) shows linear relations between the peak current (I_p) and zileuton concentration (C) and was found in the following range: 1×10^{-6} to $1.8 \times 10^{-5} \text{ mol/L}$.

Fig. 11. Square-wave voltammograms with increasing concentration ($1 \times 10^{-6} - 1.8 \times 10^{-5} \text{ mol/L}$) of zileuton in pH 8 buffer solution on GCE electrode

Fig. 12. Calibration graphs of zileuton drug by using SWV method

Validation of analytical procedure: The linearity of calibration curve was obtained for both DPV and SWV techniques and the loss of linearity was probably due to the adsorption of zileuton on the electrode surface. The characteristics of these graphs are given in Table-1. The precision of the method was investigated by repeatedly ($n = 5$) measuring peak potential and peak current of zileuton within a day and over three consecutive days for both techniques. LOD and LOQ were calculated as (3.3 s/m) and (10 s/m) , respectively where s is standard deviation of response (five runs) and m is the slope of the calibration curve. LOD and LOQ values confirmed the sensitivity of the proposed methods, These results demonstrated good precision and accuracy [23,26].

Determination of zileuton in pharmaceutical: Both proposed methods (DPV and SWV) were applied to the direct determination of zileuton in tablet using the related calibration curve of the straight lines without sample preparation and after

TABLE-1
CHARACTERISTICS OF ZILEUTON CALIBRATION
PLOTS USING PROPOSED VOLTAMMETRIC METHODS

Parameters	Differential pulse voltammetry	Square wave voltammetry
Concentration range (mol/L)	2×10^{-6} - 1.2×10^{-5}	1×10^{-6} - 1.8×10^{-5}
Slope (μA . mol/L)	0.9281	5.4887
Intercept (μA)	0.7121	0.2452
Correlation coefficient (r)	0.9988	0.9973
SD	3.67×10^{-10}	3.84×10^{-10}
RSD (%)	0.0489	0.0885
LOD (mol/L)	1.3×10^{-9}	2.34×10^{-10}
LOQ (mol/L)	3.95×10^{-9}	6.99×10^{-10}

an adequate dilution (Table-2). The proposed analysis procedure was successfully applied for the assay of zileuton in its pharmaceutical dosage form. As far as, there is no official method in any pharmacopoeias related to pharmaceutical preparations of zileuton. For this reason, HPLC method [15] was used for comparison and for the reliability of the developed procedures. The results obtained for the formulation are listed in Table-2 and compared with HPLC. The recovery studies were carried out by adding the known amount of pure drug to earlier analyzed pharmaceutical formulations of zileuton. The recovery of the drug was calculated by comparing the concentration obtained from the spiked mixtures with those of pure drug [23]. Table-2 shows a good result, which demonstrates the selectivity of proposed method for the determination of zileuton in commercial tablet forms.

Application on spiked biological samples: The optimized procedure has been successfully applied for the determination of zileuton in protein-free spiked human serum and urine samples. Acetonitrile is tried as a serum and urine precipitating agent. No extraction steps other than the centrifugal protein separation are required prior to the assay of drug. Calibration equation parameters and validation data are shown in Table-3. The obtained recovery results of spiked human serum samples are given in Table-3. The recovery results of zileuton in serum and urine samples are calculated from the related linear regression equations. DPV and SWV curves of zileuton in serum and

urine samples are examined and typically compared with that obtained from row material. It could be seen that no oxidation of zileuton drug occurs and no extra peaks are detected in tested biological material in the potential range; whereas the analytical peak appeared.

Conclusion

In conclusion, the present work demonstrates that highly sensitive electrochemical measurement of zileuton drug is feasible utilizing its extraction on to GCE. The proposed methods showed advantages, such as a short period of the real time of drug analysis and no pretreatment or time consuming in extraction steps were required prior to analysis. Moreover, because of its very limits of detection and quantification, the proposed methods applied in pharmaceutical dosage forms. It also has been successfully applied to the determination of drug in serum and urine.

ACKNOWLEDGEMENTS

Deanship of Scientific Research of Najran University has supported this work (Project No.: NU/MID/15/001).

REFERENCES

1. R.B. Bell, P.R. Young, D. Albert, C. Lanni, J.B. Summers, D.W. Brooks, P. Rubin and G.W. Carter, *Int. J. Immunopharmacol.*, **14**, 505 (1992); [https://doi.org/10.1016/0192-0561\(92\)90182-K](https://doi.org/10.1016/0192-0561(92)90182-K).
2. S.E. Wenzel and A.K. Kamada, *Ann. Pharmacother.*, **30**, 858 (1996).
3. E. Israel, R. Dermarkarian, M. Rosenberg, R. Sperling, G. Taylor, P. Rubin and J.M. Drazen, *N. Engl. J. Med.*, **323**, 1740 (1990); <https://doi.org/10.1056/NEJM199012203232505>.
4. E. Gounaris, M.J. Heiferman, J.R. Heiferman, M. Shrivastav, D. Vitello, N.R. Blatner, L.M. Knab, J.P. Phillips, E.C. Cheon, P.J. Grippo, K. Khazaie, H.G. Munshi and D.J. Bentrem, *PLoS One*, **6**, 1 (2015); <https://doi.org/10.1371/journal.pone.0121402>.
5. N. Morina, G. Bocari, A. Iljazi, K. Hyseini and G. Halac, *Acta Inform. Med.*, **24**, 16 (2016); <https://doi.org/10.5455/aim.2016.24.16-19>.
6. W. Berger, M.T. De Chandt and C.B. Cairns, *Int. J. Clin. Pract.*, **61**, 663 (2007); <https://doi.org/10.1111/j.1742-1241.2007.01320.x>.
7. P. Lu, M.L. Schrag, D.E. Slaughter, C.E. Raab, M. Shou and A.D. Rodrigues, *Drug Metab. Dispos.*, **31**, 1352 (2003); <https://doi.org/10.1124/dmd.31.11.1352>.

TABLE-2
EVALUATION OF THE ACCURACY AND PRECISION OF THE PROPOSED AND OFFICIAL METHODS
FOR THE DETERMINATION OF ZILEUTON IN ITS PHARMACEUTICAL FORMS AT GCE

Method	Drug	Taken ($\mu\text{g/mL}$)	Proposed method $\pm$ % RSD, n = 5	Official method $\pm$ % RSD, n = 5	F-test	T-test
Differential pulse voltammetry	600 mg/tablet	2.5	100.02 ± 0.12	99.91 ± 1.3	1.13	2.04
Square wave voltammetry	600 mg/tablet	2.5	99.98 ± 0.94	99.74 ± 1.00	1.85	2.23

T-value = 2.77, Tabulated F-value = 6.39 at 95 % confidence limit.

TABLE-3
ANALYTICAL RESULTS FOR ZILEUTON DRUG RECOVERIES FROM URINE AND SERUM SAMPLES

Technique	Differential pulse voltammetry		Square wave voltammetry	
	Serum	Urine	Serum	Urine
Concentration range (mol/L)	2×10^{-6} - 1.8×10^{-5}	2×10^{-6} - 2.4×10^{-5}	2×10^{-6} - 2.0×10^{-5}	2×10^{-6} - 3.1×10^{-5}
Slope (μA . mol/L)	0.2240	0.074	0.145	0.097
Intercept (μA)	1.136×10^{-6}	0.446×10^{-6}	0.345×10^{-6}	0.168×10^{-6}
Correlation coefficient (r)	0.9920	0.9935	0.9958	0.9967
Recovery (%)	99.35	100.86	99.04	99.51
RSD (%)	0.151	0.105	0.246	0.196

8. Y. Qiu, H. Cheskin, J. Briskin and K. Engh, *J. Control. Rel.*, **45**, 249 (1997); [https://doi.org/10.1016/S0168-3659\(96\)01574-X](https://doi.org/10.1016/S0168-3659(96)01574-X).
9. C.C. Zouboulis, *Dermatoendocrinol.*, **1**, 188 (2009); <https://doi.org/10.4161/derm.1.3.8368>.
10. K.K. Ananda and B.N. Naresh, *Int. Res. J. Pharmacy*, **3**, 154 (2012).
11. K.V. Prasada Rao, M. Tanuja, Y.S. Rao, T.H. Kumar, *Int. J. Res. Pharm. Chem.*, **5**, 251 (2015).
12. G.R. Granneman, R.A. Braeckman and K.A. Erdman, *Clin. Pharmacokin.*, **29**(Suppl. 2), 1 (1995); <https://doi.org/10.2165/00003088-199500292-00003>.
13. J. Song, Y.B. Zhou, J.S. Ding, *Central South Pharmacy*, 343 (2005).
14. P. Pian, E. Labovitz, K. Hoffman, C.F. Clavijo, R. Rzasa Lynn, J.L. Galinkin, A.A. Vinks, P. Malik and U. Christians, *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.*, **937**, 79 (2013); <https://doi.org/10.1016/j.jchromb.2013.08.014>.
15. S.B. Ganorkar and A.A. Shirkhedkar, *Arab. J. Chem.*, **10**, 360 (2017); <https://doi.org/10.1016/j.arabjc.2013.05.013>.
16. V.K. Prasada Rao, M. Tanuja, Y. Srinivasa Rao and H.T. Kumar, *Int. J. Drug Dev. Res.*, **7**, 101 (2015).
17. S.B. Ganorkar, A.A. Dhumal and A.A. Shirkhedkar, *Arab. J. Chem.*, **10**, 273 (2017); <https://doi.org/10.1016/j.arabjc.2014.03.009>.
18. N.Y. Sreedhar, M.S. Nayak, K.S. Prasad, P.R. Prasad and C.N. Reddy, *E-J. Chem.*, **7**, 166 (2010); <https://doi.org/10.1155/2010/251415>.
19. P. Katakam, K.A. Shanta and K. Rama Rao, *Sci. Pharm.*, **82**, 617 (2014); <https://doi.org/10.3797/scipharm.1403-20>.
20. H.M. Elqudaby, G.M. Gehad and G.M.G. El Din, *Int. J. Electrochem. Sci.*, **9**, 856 (2014).
21. M. Mazloum-Ardakani, H. Rajabi and H. Biotollahi, *J. Argent. Chem. Soc.*, **97**, 106 (2009).
22. H.M. Elqudaby, G.G. Mohamed, F.A. Ali and S.M. Eid, *Arab. J. Chem.*, **6**, 327 (2013); <https://doi.org/10.1016/j.arabjc.2011.05.019>.
23. B. Uslu, S.A. Özkan and Z. Sentürk, *Anal. Chim. Acta*, **555**, 341 (2006); <https://doi.org/10.1016/j.aca.2005.09.034>.
24. W. Xu, R. Lei, W. Cao, C. Guo, X. Zhang and S. Wang, *J. Anal. Sci. Meth. Instr.*, **3**, 75 (2013); <https://doi.org/10.4236/jasmi.2013.32009>.
25. M.E. Swartz and I.S. Krull, *Analytical Method Development and Validation*, Marcel Dekker: New York, edn 1 (1997).
26. J. Ermer and J.H. Miller, *Method Validation in Pharmaceutical Analysis; A Guide to Best Practice*, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, pp. 301-336 (2005).